Biogen Inc. (BIIB)
Company Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.
It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies.
In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development.
It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Country | United States |
Founded | 1978 |
IPO Date | Sep 16, 1991 |
Industry | Drug Manufacturers - General |
Sector | Healthcare |
Employees | 7,570 |
CEO | Christopher A. Viehbacher |
Contact Details
Address: 225 Binney Street Cambridge, Massachusetts 02142 United States | |
Phone | (781) 464-2000 |
Website | biogen.com |
Stock Details
Ticker Symbol | BIIB |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000875045 |
CUSIP Number | 09062X103 |
ISIN Number | US09062X1037 |
Employer ID | 33-0112644 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Christopher A. Viehbacher | President, Chief Executive Officer and Director |
Michael R. McDonnell CPA | Executive Vice President and Chief Financial Officer |
Nicole Murphy | Head of Pharmaceutical Operations and Technology |
Susan H. Alexander Esq. | Executive Vice President and Chief Legal Officer |
Dr. Ginger Gregory | Executive Vice President and Chief Human Resources Officer |
Robin C. Kramer | Senior Vice President and Chief Accounting Officer |
Charles E. Triano | Senior Vice President and Head of Investor Relations |
Natacha Gassenbach | Chief Communication Officer and Head of Corporate Affairs |
Adam Keeney Ph.D. | Executive Vice President and Head of Corporate Development |
Alisha A. Alaimo | President and Head of North America |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 22, 2024 | 144 | Filing |
Feb 21, 2024 | 144 | Filing |
Feb 14, 2024 | 10-K | Annual Report |
Feb 13, 2024 | 8-K | Current Report |
Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 12, 2024 | 144 | Filing |
Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 2, 2024 | 144 | Filing |
Jan 24, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |